A next-generation beneficial microbe: Akkermansia muciniphila
- PMID: 30087541
- PMCID: PMC6064808
- DOI: 10.3164/jcbn.18-57
A next-generation beneficial microbe: Akkermansia muciniphila
Abstract
There have been many reports on the roles of intestinal flora and intestinal environment in health promotion and disease prevention. Beneficial bacteria such as Bifidobacterium and lactic acid-producing bacteria have been shown to improve the intestinal environment, and yield a good effect on metabolism, immunity and nerve response. In this review, in addition to these beneficial bacteria, we introduced Akkermansia muciniphila as a next-generation beneficial microbe. Several reports indicate that Akkermansia muciniphila affects glucose metabolism, lipid metabolism, and intestinal immunity, and that certain food ingredients such as polyphenols may increase the abundance of Akkermansia muciniphila in the gut.
Keywords: Akkermansia muciniphila; cancer immunotherapy; diabetes; polyphenols.
Conflict of interest statement
YN received scholarship fund from EA Pharma. Co. Ltd. and collaboration research fund from Fujifilm Medical Co. Ltd., and has been paid lecture fees by Janssen Pharma KK, Mylan EPD Co., Takeda Pharma. Co. Ltd., Mochida Pharm. Co. Ltd., EA Pharma. Co. Ltd., Otsuka Pharma. Co. Ltd., and Astellas Pharma. Co. Ltd. TT received lecture fees by Mochida Pharm. Co. Ltd. and Mitsubishi Tanabe Pharama Co. The other authors have no conflicts of interest to declare.
Figures
References
-
- Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54 (Pt 5):1469–1476. - PubMed
-
- Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014;63:1513–1521. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
